Deleveraging Sanofi trims syndicate for €3bn revolver
Sanofi-Aventis, the pharmaceutical firm, has managed to cut the size of the bank group on its new €3bn facility but demand for the A1/AA-/AA- rated company’s paper has meant that some banks have also joined the syndicate.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
